These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20148563)

  • 1. BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring.
    Nourry A; Zambon A; Davies L; Niculescu-Duvaz I; Dijkstra HP; Ménard D; Gaulon C; Niculescu-Duvaz D; Suijkerbuijk BM; Friedlos F; Manne HA; Kirk R; Whittaker S; Marais R; Springer CJ
    J Med Chem; 2010 Mar; 53(5):1964-78. PubMed ID: 20148563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic group.
    Suijkerbuijk BM; Niculescu-Duvaz I; Gaulon C; Dijkstra HP; Niculescu-Duvaz D; Ménard D; Zambon A; Nourry A; Davies L; Manne HA; Friedlos F; Ogilvie LM; Hedley D; Lopes F; Preece NP; Moreno-Farre J; Raynaud FI; Kirk R; Whittaker S; Marais R; Springer CJ
    J Med Chem; 2010 Apr; 53(7):2741-56. PubMed ID: 20199087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors.
    Zambon A; Ménard D; Suijkerbuijk BM; Niculescu-Duvaz I; Whittaker S; Niculescu-Duvaz D; Nourry A; Davies L; Manne HA; Lopes F; Preece N; Hedley D; Ogilvie LM; Kirk R; Marais R; Springer CJ
    J Med Chem; 2010 Aug; 53(15):5639-55. PubMed ID: 20597484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring.
    Ménard D; Niculescu-Duvaz I; Dijkstra HP; Niculescu-Duvaz D; Suijkerbuijk BM; Zambon A; Nourry A; Roman E; Davies L; Manne HA; Friedlos F; Kirk R; Whittaker S; Gill A; Taylor RD; Marais R; Springer CJ
    J Med Chem; 2009 Jul; 52(13):3881-91. PubMed ID: 19473026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer profile of newly synthesized BRAF inhibitors possess 5-(pyrimidin-4-yl)imidazo[2,1-b]thiazole scaffold.
    Abdel-Maksoud MS; Ammar UM; Oh CH
    Bioorg Med Chem; 2019 May; 27(10):2041-2051. PubMed ID: 30955995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
    Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
    Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of novel imidazole derivatives possessing terminal sulphonamides as potential BRAF
    Ali EMH; Abdel-Maksoud MS; Ammar UM; Mersal KI; Ho Yoo K; Jooryeong P; Oh CH
    Bioorg Chem; 2021 Jan; 106():104508. PubMed ID: 33280830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 3H-imidazo[4,5-b]pyridines as potent c-Met kinase inhibitors: design, synthesis, and biological evaluation.
    Chen D; Wang Y; Ma Y; Xiong B; Ai J; Chen Y; Geng M; Shen J
    ChemMedChem; 2012 Jun; 7(6):1057-70. PubMed ID: 22581753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]pyridin-2-one-Based p38 MAP Kinase Inhibitors: Part 1.
    Kaieda A; Takahashi M; Fukuda H; Okamoto R; Morimoto S; Gotoh M; Miyazaki T; Hori Y; Unno S; Kawamoto T; Tanaka T; Itono S; Takagi T; Sugimoto H; Okada K; Snell G; Bertsch R; Nguyen J; Sang BC; Miwatashi S
    ChemMedChem; 2019 May; 14(10):1022-1030. PubMed ID: 30945818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents.
    Niculescu-Duvaz D; Niculescu-Duvaz I; Suijkerbuijk BM; Ménard D; Zambon A; Davies L; Pons JF; Whittaker S; Marais R; Springer CJ
    Bioorg Med Chem; 2013 Mar; 21(5):1284-304. PubMed ID: 23376011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential BRAF(V600E) inhibitors.
    Wang SF; Zhu YL; Zhu PT; Makawana JA; Zhang YL; Zhao MY; Lv PC; Zhu HL
    Bioorg Med Chem; 2014 Nov; 22(21):6201-8. PubMed ID: 25267006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of imidazothiazole derivatives gives promising activity in B-Raf kinase enzyme inhibition; synthesis, in vitro studies and molecular docking.
    Ammar UM; Abdel-Maksoud MS; Mersal KI; Ali EMH; Yoo KH; Choi HS; Lee JK; Cha SY; Oh CH
    Bioorg Med Chem Lett; 2020 Oct; 30(20):127478. PubMed ID: 32781217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment.
    Smalley KS; Flaherty KT
    Future Oncol; 2009 Aug; 5(6):775-8. PubMed ID: 19663727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors.
    Dietrich J; Gokhale V; Wang X; Hurley LH; Flynn GA
    Bioorg Med Chem; 2010 Jan; 18(1):292-304. PubMed ID: 19962319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and evaluation of novel diaryl urea derivatives as potential antitumor agents.
    Lu C; Tang K; Li Y; Li P; Lin Z; Yin D; Chen X; Huang H
    Eur J Med Chem; 2014 Apr; 77():351-60. PubMed ID: 24675135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitors.
    Smith A; Ni ZJ; Poon D; Huang Z; Chen Z; Zhang Q; Tandeske L; Merritt H; Shoemaker K; Chan J; Kaufman S; Huh K; Murray J; Appleton BA; Cowan-Jacob SW; Scheufler C; Kanazawa T; Jansen JM; Stuart D; Shafer CM
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5221-5224. PubMed ID: 29107542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors.
    Kim M; Lee J; Jung K; Kim H; Aman W; Ryu JS; Hah JM
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3600-4. PubMed ID: 24878193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF).
    Niculescu-Duvaz D; Gaulon C; Dijkstra HP; Niculescu-Duvaz I; Zambon A; Ménard D; Suijkerbuijk BM; Nourry A; Davies L; Manne H; Friedlos F; Ogilvie L; Hedley D; Whittaker S; Kirk R; Gill A; Taylor RD; Raynaud FI; Moreno-Farre J; Marais R; Springer CJ
    J Med Chem; 2009 Apr; 52(8):2255-64. PubMed ID: 19323560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of diarylthiazole B-raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effect.
    Pulici M; Traquandi G; Marchionni C; Modugno M; Lupi R; Amboldi N; Casale E; Colombo N; Corti L; Fasolini M; Gasparri F; Pastori W; Scolaro A; Donati D; Felder E; Galvani A; Isacchi A; Pesenti E; Ciomei M
    ChemMedChem; 2015 Feb; 10(2):276-95. PubMed ID: 25430902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, in vitro antiproliferative evaluation, and kinase inhibitory effects of a new series of imidazo[2,1-b]thiazole derivatives.
    Abdel-Maksoud MS; Kim MR; El-Gamal MI; Gamal El-Din MM; Tae J; Choi HS; Lee KT; Yoo KH; Oh CH
    Eur J Med Chem; 2015 May; 95():453-63. PubMed ID: 25841200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.